Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$31.73 - $49.19 $247,494 - $383,682
-7,800 Reduced 84.78%
1,400 $66,000
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $216,504 - $289,292
6,200 Added 206.67%
9,200 $327,000
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $112,050 - $156,450
3,000 New
3,000 $138,000
Q4 2022

Feb 14, 2023

SELL
$33.72 - $46.33 $202,320 - $277,980
-6,000 Reduced 56.07%
4,700 $217,000
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $423,576 - $701,084
10,600 Added 10600.0%
10,700 $443,000
Q2 2022

Aug 08, 2022

SELL
$45.8 - $85.4 $247,319 - $461,160
-5,400 Reduced 98.18%
100 $6,000
Q1 2022

May 16, 2022

BUY
$62.2 - $84.4 $130,620 - $177,240
2,100 Added 61.76%
5,500 $399,000
Q4 2021

Feb 14, 2022

BUY
$73.71 - $87.86 $250,613 - $298,724
3,400 New
3,400 $286,000
Q2 2021

Aug 16, 2021

SELL
$92.19 - $115.71 $894,243 - $1.12 Million
-9,700 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$106.9 - $167.73 $652,090 - $1.02 Million
6,100 Added 169.44%
9,700 $1.1 Million
Q4 2020

Feb 16, 2021

BUY
$84.4 - $177.39 $303,840 - $638,604
3,600 New
3,600 $498,000
Q3 2020

Nov 16, 2020

SELL
$72.98 - $90.0 $386,794 - $477,000
-5,300 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$46.91 - $78.22 $248,622 - $414,566
5,300 New
5,300 $415,000
Q2 2019

Aug 14, 2019

SELL
$54.93 - $74.36 $1.02 Million - $1.38 Million
-18,500 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$39.87 - $69.36 $737,595 - $1.28 Million
18,500 New
18,500 $1.28 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.13B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.